Advent acquires majority stake in NZCR Group
Worldwide private equity firm Advent is acquiring a controlling stake in clinical research group NZCR Group; financial terms stay secret, and existing shareholders keep a sizeable minority holding.
Investor
Every published round Waterman Capital took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Waterman Capital has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Fund closes reported for Waterman Capital, as distinct from the investments it has made.
Companies Waterman Capital has backed that another company then bought. An exit for the holding, not a deal Waterman Capital did.
Stories naming Waterman Capital. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Worldwide private equity firm Advent is acquiring a controlling stake in clinical research group NZCR Group; financial terms stay secret, and existing shareholders keep a sizeable minority holding.
Advent International is to take a majority holding in trans-Tasman clinical trials operator NZCR, whose existing backers, among them Waterman Capital, will keep a minority position, with a fourth-quarter close anticipated.
Also adventinternational.com·nzcr.co.nz·biospectrumasia.com·healthcaredealflow.com